The 10-second takeaway
For the quarter ended Dec. 31 (Q4), WebMD Health beat slightly on revenues and whiffed on earnings per share.
Compared to the prior-year quarter, revenue dropped and GAAP earnings per share dropped significantly.
Margins shrank across the board.
WebMD Health reported revenue of $150.7 million. The six analysts polled by S&P Capital IQ expected sales of $149.1 million on the same basis. GAAP reported sales were 11% lower than the prior-year quarter's $168.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.24. The nine earnings estimates compiled by S&P Capital IQ predicted $0.37 per share on the same basis. GAAP EPS of $0.33 for Q4 were 46% lower than the prior-year quarter's $0.61 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 64.8%, 440 basis points worse than the prior-year quarter. Operating margin was 24.5%, 680 basis points worse than the prior-year quarter. Net margin was 12.7%, 900 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $108.0 million. On the bottom line, the average EPS estimate is -$0.07.
Next year's average estimate for revenue is $516.7 million. The average EPS estimate is $0.32.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 102 members out of 159 rating the stock outperform, and 57 members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 31 give WebMD Health a green thumbs-up, and 20 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on WebMD Health is hold, with an average price target of $36.80.
Internet software and services are being consumed in radically different ways, on new and increasingly mobile devices. Is WebMD Health on the right side of the revolution? Check out the changing landscape and meet the company that Motley Fool analysts expect to lead "The Next Trillion-Dollar Revolution." Click here for instant access to this free report.
- Add WebMD Health to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.